治疗剂量^(131)I SPECT/CT显像评价分化型甲状腺癌骨转移  

Application of ^(131)I SPECT / CT Fusion Imaging for Evaluating Bone Metastasis in Patients with DTC

作　　者：程旭[1] 李永军[1] 徐兆强[1] 袁孝军[1] 许昕丹 包丽华[1] 

机构地区：[1]南京医科大学第一附属医院核医学科,江苏南京210029

出　　处：《标记免疫分析与临床》2015年第11期1095-1098,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨^(131)I SPECT/CT断层融合显像在评价分化型甲状腺癌(DTC)骨转移中的价值。方法 30例确诊为骨转移的DTC患者纳入本研究,其中男14例,女16例,平均年龄54.3±12.6岁。在口服治疗剂量131I后的80~96小时完成^(131)I全身平面显像和SPECT/CT断层融合显像。结果 30例患者中单发性骨转移8例,多发性骨转移22例。单发性骨转移的病灶分别位于胸骨、颈椎、胸椎、股骨、锁骨、颅骨和肋骨。22例多发骨转移患者的病灶主要位于脊柱、肋骨、胸骨和骨盆骨等。所有患者的SPECT/CT图像上均可见^(131)I异常放射性浓聚,同机CT示24例为骨破坏,1例为成骨性改变,CT结果为阴性者5例。多发骨转移组的血清甲状腺球蛋白(Tg)明显高于单发骨转移组(P=0.018),两组血清甲状腺球蛋白抗体(A-Tg)并无明显差别(P=0.212)。结论^(131)I SPECT/CT断层融合显像可以较好的将代谢信息和解剖结构信息相结合,更好的评价DTC患者的骨转移。Objective To evaluate the clinical value of ^（131）I SPECT / CT fusion imaging for evaluating bone metastasis in patients with differentiated thyroid cancer（ DTC）. Methods 30 DTC patients with bone metastasis were included in our study. All patients were performed ^（131）I whole-body planar imaging and regional SPECT / CT fusion imaging after 80-96 hours oral uptake of therapeutic ^（131）I. Results Of all 30 patients,8 patients＇ lesions of bone metastasis located at single region and 22 patients＇ bone metastasis were multiple lesions. Single lesion of 8 patients located at sternum,cervical spine,thoracic vertebrae,femoral,clavicle and rib. Multiple bone metastasis lesions of 22 patients were mainly located at spine,rib,clavicle and pelvic bone. Abnormal accumulations of ^（131）I were seen on SPECT / CT images in all 30 patients. 24 patients showed bone destruction on CT images,1 patient showed osteoblastic change,and 5 patients were negative on CT images. The serum Tg level in patients with multiple bone metastases was higher than that of patients with single bone metastasis.Conclusion ^（131）I SPECT / CT fusion imaging could be used to evaluate bone metastasis in patients with DTC.

关 键 词：甲状腺肿瘤 碘放射性同位素 放射性核素显像 体层摄影术 发射型计算机 单光子 

分 类 号：R736.1[医药卫生—肿瘤]